Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina, Inc. (NASDAQ: ILMN) is at the forefront of genomic technology, providing innovative tools and services to analyze genetic material. With a primary focus on DNA sequencing and array-based technologies, Illumina serves a diverse range of markets including life sciences, oncology, reproductive health, and agriculture. Over 90% of its revenue stems from sequencing instruments, consumables, and services, with the remainder coming from microarrays used in genetic screening for consumer and agricultural applications. Illumina's technology enables high-throughput whole genome sequencing, which is essential for large-scale genomic studies, as well as lower throughput tools for specific applications such as viral and cancer tumor screening.
Recent advancements at Illumina include the upcoming release of their first quarter 2024 financial results, showcasing significant improvements in both gross and non-GAAP operating margins. The company's innovative solutions continue to drive sequencing activity globally, despite challenging economic conditions. Illumina's NovaSeq X Sequencing System exemplifies their cutting-edge research and development efforts, demonstrating the company's commitment to delivering superior technology for genomic analysis.
In the oncology domain, Illumina's Whole-Genome Sequencing (WGS) and Comprehensive Genomic Profiling (CGP) are setting new standards for cancer diagnostics and treatment. By collaborating with leading institutions and pharmaceutical companies, Illumina is enhancing the scientific understanding of cancer biology and developing advanced assays for Molecular Residual Disease (MRD) detection. These efforts are crucial in precision oncology, enabling early detection and personalized treatment strategies.
Illumina is also committed to expanding access to genomic testing. Through initiatives like The Future Is Bright and partnerships with educational institutions, the company is fostering the next generation of scientists. Their volunteer programs and educational outreach aim to increase genomic literacy and inspire students to pursue careers in STEM fields.
Furthermore, Illumina's ongoing collaboration with GRAIL, Inc., a wholly-owned subsidiary focused on early cancer detection, highlights the company's dedication to transformative healthcare solutions. Despite regulatory challenges, Illumina remains steadfast in its mission to unlock the power of the genome and improve human health.
Stay updated with Illumina's latest developments and financial performance by visiting their website and connecting on social media platforms like X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Illumina (NASDAQ: ILMN) has announced a strategic collaboration with Broad Clinical Labs to scale single-cell research projects using advanced tools and workflows. The partnership aims to create a 5 billion cell atlas within three years, leveraging Illumina's Single Cell Prep, NovaSeq™ X Plus platform, 25B flow cell, and DRAGEN™ analysis software.
The collaboration combines Illumina's sequencing expertise with Broad's experience in translating complex molecular biology assays into high-throughput workflows. The partnership will utilize cutting-edge techniques like Perturb-seq and CRISPR screens to process and analyze large volumes of single-cell reads, accelerating discoveries in disease modeling and drug development.
This end-to-end workflow solution aims to enable high-throughput processing of single-cell samples with enhanced speed and accuracy, supporting the development of large-scale functional genomics studies.
Illumina (NASDAQ: ILMN) has announced a groundbreaking spatial technology program that will enable researchers to map complex tissues and understand cellular behavior at unprecedented scale. The technology, planned for commercial release in 2026, offers nine times larger capture area and four times greater resolution than existing technologies.
The company is partnering with the Broad Institute on a Spatial Flagship Project to demonstrate the potential of large-scale spatial datasets. The technology will be compatible with Illumina NextSeq and NovaSeq sequencers and will be paired with a new software platform, Illumina Connected Multiomics (ICM), for multimodal analysis.
Early research applications have shown promising results in studies of pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains. The technology enables examination of spatial proximity of millions of cells per experiment, identification of rare cell populations, and improved statistical power.
Illumina (NASDAQ: ILMN) has announced a live webcast of its upcoming investor session at the Advances in Genome Biology and Technology (AGBT) Conference. The investor fireside chat is scheduled for Tuesday, February 25, 2025, at 8:00am PT (11:00am ET).
The session will feature presentations from key executives including Jacob Thaysen (CEO), Ankur Dhingra (CFO), and Steve Barnard (CTO). Investors, analysts, and interested parties can access the webcast through Illumina's website Investor Info section or via the provided direct link.
Participants are advised to join ten minutes before the scheduled start time to ensure proper connection. A replay of the session will be available on Illumina's website for at least 30 days after the event.
Illumina (ILMN) reported Q4 2024 Core revenue of $1.1 billion, up 1% year-over-year, while fiscal year 2024 revenue decreased 2% to $4.3 billion. The company achieved strong Q4 performance with GAAP operating margin of 15.8% and non-GAAP operating margin of 19.7%.
For Q4 2024, GAAP diluted EPS was $0.73 and non-GAAP diluted EPS reached $0.95. The full fiscal year 2024 saw GAAP diluted EPS of $5.61 and non-GAAP diluted EPS of $4.16. Cash flow remained robust with $1.2 billion provided by operations and $1.1 billion in free cash flow for fiscal year 2024.
Looking ahead to 2025, Illumina projects low single-digit Core revenue growth with expected revenue between $4.28-4.4 billion and non-GAAP operating margin of approximately 23%. The company forecasts non-GAAP diluted EPS between $4.50-4.65, excluding potential impacts from recent China Ministry of Commerce announcements.
Illumina (NASDAQ: ILMN) has released preliminary unaudited financial results for Q4 and fiscal year 2024, along with its 2025 outlook. The company reported Q4 2024 revenue of $1.10 billion, up 1% year-over-year, while full-year 2024 revenue decreased 2% to $4.33 billion.
Q4 2024 performance showed GAAP operating margin of 16.7% and non-GAAP operating margin of 19.7%. For the full year 2024, GAAP operating margin was 34.2% and non-GAAP operating margin was 21.3%. The company achieved GAAP diluted EPS of $0.77-$0.79 for Q4 and $5.65-$5.67 for 2024.
Looking ahead to 2025, Illumina expects low single-digit constant currency revenue growth with revenue projected between $4.28 billion to $4.4 billion, non-GAAP operating margin of approximately 23%, and non-GAAP diluted EPS growth of approximately 10%.
Illumina (NASDAQ: ILMN) has announced a strategic collaboration with NVIDIA to advance technology platforms for multiomic data analysis and interpretation. The partnership combines Illumina's sequencing technologies and Connected Software with NVIDIA's AI tools to accelerate progress in clinical research, genomics AI development, and drug discovery.
The collaboration will integrate NVIDIA's RAPIDS™ data science software, BioNeMo™ platform's generative AI models, and MONAI spatial cell imaging workflows with Illumina's Connected Analytics platform. In the first phase, they will focus on enabling DRAGEN algorithms on NVIDIA GPUs and incorporating NVIDIA's image processing and single-cell tertiary analysis tools into Illumina's multiomics module.
Illumina brings its expertise in AI for genomic interpretation, including SpliceAI, PrimateAI-3D, and Emedgene xAI algorithms, while expanding customer offerings with models developed by NVIDIA's Biology Foundation Model Research Team.
Illumina (NASDAQ: ILMN) has announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with multiple partners including deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The program will utilize Illumina's upcoming Illumina Protein Prep™ solution, which can detect 9,000 unique human proteins.
The first 30,000 samples, funded through coinvestment from Illumina, deCODE Genetics, and Standard BioTools, will be made available to the scientific research community in the second half of 2025. The remaining 20,000 samples will initially be accessible exclusively to industry consortium members before wider release. The project aims to generate high-quality proteomics data to advance biological insights and facilitate biomarker discovery for conditions like cancer and cardiovascular disease.
The Illumina Protein Prep solution, scheduled for launch in first half 2025, is compatible with NovaSeq X, NovaSeq X Plus, and NovaSeq 6000 Systems.
Illumina (NASDAQ:ILMN) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 6, 2025, after market close. The company will host a conference call at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
CEO Jacob Thaysen and CFO Ankur Dhingra will lead the conference call to discuss financial and operating results with analysts, investors, and other interested parties. The live webcast will be accessible through Illumina's Investor Info section, with participants advised to join at least ten minutes before the scheduled start time. A replay will be available on the company's website for a minimum of 30 days following the event.
Illumina (NASDAQ: ILMN) has announced significant updates to its NovaSeq X Series, including a new single-flow-cell system, software upgrade v1.3, and new 25B kits. The single-flow-cell system offers the same quality and speed as the NovaSeq X Plus at a more accessible cost for lower-volume labs. The v1.3 software upgrade enhances sequencing performance with improved accuracy and higher yields.
The company began shipping new NovaSeq X 25B 100-cycle and 200-cycle kits in December, optimized for counting applications and assays at scale. Additionally, Illumina launched Single-Cell Prep (formerly Fluent PipSeq V), compatible with NextSeq 1000/2000, NovaSeq 6000, and NovaSeq X platforms. This technology enables scalable experiments from hundreds to millions of cells, offering lower equipment and per-cell costs.
Illumina, a global genomics leader, showcases employee perspectives on working in genomics technology through a video feature. The company highlights how their work impacts global human health through next-generation sequencing solutions across research, clinical, and applied markets. Three Illumina professionals share their experiences and motivations for working at the company, emphasizing their contribution to advancing personalized healthcare. The company's technology supports innovations in various fields, including oncology, reproductive health, genetic disease, microbiology, agriculture, and forensic science.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
What does Illumina, Inc. specialize in?
What are Illumina's main revenue sources?
How is Illumina contributing to cancer research?
What are some recent achievements of Illumina?
What is the role of GRAIL in Illumina's operations?
How is Illumina expanding genomic literacy?
Where can one find Illumina's latest news and updates?
What types of genomic analysis does Illumina technology support?
What educational programs does Illumina offer?
How is Illumina addressing the global cancer burden?
